Brivudine: Difference between revisions
m (Protected "Brivudine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
{{Drugbox| | |||
|IUPAC_name = 5-[(''E'')-2-bromoethenyl]-1-[(2''R'',4''S'',5''R'')-4-hydroxy- | {{Drugbox | ||
| image=Brivudine. | | Verifiedfields = changed | ||
| CAS_number=69304-47-8 | | verifiedrevid = 459982797 | ||
| ATC_prefix=J05 | | IUPAC_name = 5-[(''E'')-2-bromoethenyl]-1-[(2''R'',4''S'',5''R'')-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione | ||
| ATC_suffix=AB15 | | image = Brivudine.png | ||
| PubChem=446727 | |||
| | <!--Clinical data--> | ||
| C = 11 | H = 13 | Br = 1 | N = 2 | O = 5 | | tradename = | ||
| Drugs.com = {{drugs.com|international|brivudine}} | |||
| pregnancy_category = exclusion | |||
| legal_status = | |||
| routes_of_administration = oral | |||
<!--Pharmacokinetic data--> | |||
| bioavailability = 30% | |||
| metabolism = | |||
| elimination_half-life = 16 hours | |||
| excretion = mainly renal | |||
<!--Identifiers--> | |||
| CAS_number_Ref = {{cascite|changed|??}} | |||
| CAS_number = 69304-47-8 | |||
| ATC_prefix = J05 | |||
| ATC_suffix = AB15 | |||
| PubChem = 446727 | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 394011 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = 2M3055079H | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} | |||
| ChEMBL = 31634 | |||
<!--Chemical data--> | |||
| C=11 | H=13 | Br=1 | N=2 | O=5 | |||
| molecular_weight = 333.135 g/mol | | molecular_weight = 333.135 g/mol | ||
| | | smiles = Br[C@H]=CC=1C(=O)NC(=O)N(C=1)[C@@H]2O[C@@H]([C@@H](O)C2)CO | ||
| | | InChI = 1/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9+/m0/s1 | ||
| | | InChIKey = ODZBBRURCPAEIQ-PIXDULNEBW | ||
| | | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | ||
| | | StdInChI = 1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9+/m0/s1 | ||
| | | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | ||
| | | StdInChIKey = ODZBBRURCPAEIQ-PIXDULNESA-N | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Brivudine''' is an [[antiviral drug]] used in the treatment of [[herpes zoster]]. | '''Brivudine''' is an [[antiviral drug]] used in the treatment of [[herpes zoster]]. | ||
==History== | ==History== | ||
Brivudine is a similar drug to [[acyclovir]]. The compound was first synthesized by scientists at the [[University of Birmingham]] in the UK in the 1970s. It was shown to be a potent inhibitor of the [[herpes simplex virus]] Type 1 (HSV-1) as well as the [[varicella zoster virus]] (VZV) by Erik De Clercq at the [[Rega Institute for Medical Research]] in [[Belgium]] in 1979. In the 1980s the drug became commercially available in [[East Germany]], where it was marketed as '''Helpin''' by a pharmaceutical company called Berlin-Chemie. | Brivudine is a similar drug to [[acyclovir]]{{Clarify|date=July 2009}}. The compound was first synthesized by scientists at the [[University of Birmingham]] in the UK in the 1970s. It was shown to be a potent inhibitor of the [[herpes simplex virus]] Type 1 (HSV-1) as well as the [[varicella zoster virus]] (VZV) by [[Erik De Clercq]] at the [[Rega Institute for Medical Research]] in [[Belgium]] in 1979. In the 1980s the drug became commercially available in [[East Germany]], where it was marketed as '''Helpin''' by a pharmaceutical company called Berlin-Chemie. | ||
==Approvals== | ==Approvals== | ||
Line 26: | Line 59: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Brivudine is an analogue of the [[nucleoside]] [[thymidine]]. The drug works because it is able to be incorporated into the viral DNA, but then blocks the action of DNA [[polymerases]], thus inhibiting viral replication. | Brivudine is an analogue of the [[nucleoside]] [[thymidine]]. The drug works because it is able to be incorporated into the viral DNA, but then blocks the action of DNA [[polymerases]], thus inhibiting viral replication. The active compound is the 5'-triphosphate of BVDU, which is formed in subsequent phosphorylations by viral thymidine kinase and presumably by nucleoside diphosphate kinase. | ||
==Research== | |||
A [[Cochrane Collaboration|Cochrane Systematic Review]] examined the effectiveness of multiple antiviral drugs in the treatment of [[herpes of the eye|herpes simplex virus epithelial keratitis]]. Brivudine was found to be significantly more effective than [[idoxuridine]] in increasing the number of successfully healed eyes of participants.<ref name="Wilhelmus">{{cite journal |author= Wilhelmus KR |title= Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis |journal=Cochrane Database Syst Rev|volume=12 |pages= CD002898 |date=2010 |pmid= 21154352|doi= 10.1002/14651858.CD002898.pub4}}</ref> | |||
==The drug's name== | ==The drug's name== | ||
Brivudine derives from the drug's chemical name of bromovinyldeoxyuridine or BVDU for short. The drug's full chemical description is (E)-5-(2-bromovinyl)-2-deoxyuridine. It is also sold as Brivudin, Helpin, Zerpex, Zonavir and Zostex. | Brivudine derives from the drug's chemical name of bromovinyldeoxyuridine or BVDU for short. The drug's full chemical description is (E)-5-(2-bromovinyl)-2-deoxyuridine. It is also sold as Bridic, Brivox, Brivudin, Helpin, Zerpex, Zonavir and Zostex. | ||
==Suppliers== | ==Suppliers== | ||
Brivudine main supplier is Berlin-Chemie, now part of Italy's Menarini Group. The drug is approved for sale in Austria, Belgium, Germany, Greece, Italy, Luxembourg and Spain. | Brivudine main supplier is Berlin-Chemie, now part of Italy's Menarini Group. The drug is approved for sale in Austria, Belgium, Germany, Greece, Italy, Luxembourg, Portugal and Spain. In Central America is provided Menarini Centro America and Wyeth. | ||
==References== | |||
{{reflist|2}} | |||
{{Antivirals}} | {{Antivirals}} | ||
[[ | [[Category:Nucleosides]] | ||
[[Category:Drug]] | |||
[[Category:Organobromides]] |
Latest revision as of 20:42, 12 April 2015
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | oral |
ATC code | |
Pharmacokinetic data | |
Bioavailability | 30% |
Elimination half-life | 16 hours |
Excretion | mainly renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C11H13BrN2O5 |
Molar mass | 333.135 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Brivudine |
Articles |
---|
Most recent articles on Brivudine |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Brivudine at Clinical Trials.gov Clinical Trials on Brivudine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Brivudine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Brivudine Discussion groups on Brivudine Directions to Hospitals Treating Brivudine Risk calculators and risk factors for Brivudine
|
Healthcare Provider Resources |
Causes & Risk Factors for Brivudine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Brivudine is an antiviral drug used in the treatment of herpes zoster.
History
Brivudine is a similar drug to acyclovir[clarification needed]. The compound was first synthesized by scientists at the University of Birmingham in the UK in the 1970s. It was shown to be a potent inhibitor of the herpes simplex virus Type 1 (HSV-1) as well as the varicella zoster virus (VZV) by Erik De Clercq at the Rega Institute for Medical Research in Belgium in 1979. In the 1980s the drug became commercially available in East Germany, where it was marketed as Helpin by a pharmaceutical company called Berlin-Chemie.
Approvals
Brivudine is approved for use in Germany and other European countries including Italy.
Mechanism of Action
Brivudine is an analogue of the nucleoside thymidine. The drug works because it is able to be incorporated into the viral DNA, but then blocks the action of DNA polymerases, thus inhibiting viral replication. The active compound is the 5'-triphosphate of BVDU, which is formed in subsequent phosphorylations by viral thymidine kinase and presumably by nucleoside diphosphate kinase.
Research
A Cochrane Systematic Review examined the effectiveness of multiple antiviral drugs in the treatment of herpes simplex virus epithelial keratitis. Brivudine was found to be significantly more effective than idoxuridine in increasing the number of successfully healed eyes of participants.[1]
The drug's name
Brivudine derives from the drug's chemical name of bromovinyldeoxyuridine or BVDU for short. The drug's full chemical description is (E)-5-(2-bromovinyl)-2-deoxyuridine. It is also sold as Bridic, Brivox, Brivudin, Helpin, Zerpex, Zonavir and Zostex.
Suppliers
Brivudine main supplier is Berlin-Chemie, now part of Italy's Menarini Group. The drug is approved for sale in Austria, Belgium, Germany, Greece, Italy, Luxembourg, Portugal and Spain. In Central America is provided Menarini Centro America and Wyeth.
References
- ↑ Wilhelmus KR (2010). "Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis". Cochrane Database Syst Rev. 12: CD002898. doi:10.1002/14651858.CD002898.pub4. PMID 21154352.
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Wikipedia articles needing clarification from July 2009
- Articles with invalid date parameter in template
- Nucleosides
- Drug
- Organobromides